| Protocol No. | ClinicalTrials.gov Protocol No. | PI Name | Title | |||
| Pediatric Cancers > Solid Tumors > Neuroblastoma | ||||||
| ANBL1821 | NCT03794349 | Vo, Kieuhoa | Irinotecan Hydrochloride, Temozolomide, and Dinutuximab With or Without Eflornithine in Treating Patients With Relapsed or Refractory Neuroblastoma | |||
| ANBL19P1 | NCT04385277 | Rangaswami, Arun | Treatment With Dinutuximab, Sargramostim (GM-CSF), and Isotretinoin in Combination With Irinotecan and Temozolomide After Intensive Therapy for People With High-Risk Neuroblastoma (NBL) | |||
| IRP-101 | NCT04724369 | Vo, Kieuhoa | Open-Label Study of 18F-mFBG for Imaging Neuroblastoma | |||
| MIBG 2014-01 | NCT03561259 | Vo, Kieuhoa | A Study of Therapeutic Iobenguane (131-I) and Vorinostat for Recurrent or Progressive High-Risk Neuroblastoma Subjects (OPTIMUM) | |||
| NANT-2004-05 | NCT02868268 | Vo, Kieuhoa | Neuroblastoma Precision Trial | |||
| NANT-2015-02 | NCT03107988 | Vo, Kieuhoa | NANT 2015-02: A Phase 1 Study of Lorlatinib (PF-06463922) | |||
| NANT-2017-01 | NCT03332667 | Vo, Kieuhoa | MIBG With Dinutuximab +/- Vorinostat | |||
| 05161 | NCT00293319 | Vo, Kieuhoa | 131 I-MIBG in Treating Patients With Refractory or Relapsed Neuroblastoma | |||